Limited-stage ovarian carcinoma.

Area of Science:

• Gynecologic Oncology
• Surgical Pathology
• Clinical Oncology

Background:

• Ovarian carcinoma diagnosis lacks effective screening, resulting in advanced-stage disease at presentation for most patients.
• Early-stage ovarian cancer (FIGO stages I-II) still carries a significant risk of recurrence, necessitating risk stratification.
• Current management strategies differentiate between low-risk and high-risk early-stage disease.

Purpose of the Study:

• To define criteria for risk stratification in early-stage ovarian carcinoma.
• To outline optimal management strategies based on risk categorization.
• To evaluate the impact of adjuvant chemotherapy on recurrence rates.

Main Methods:

• Retrospective analysis of early-stage ovarian carcinoma cases.
• Categorization of patients into low-risk and high-risk groups based on histopathological and clinical features.
• Comparison of recurrence rates between observation and adjuvant chemotherapy in high-risk groups.

Main Results:

• Low-risk early-stage ovarian carcinoma (grade I, confined to ovary, negative cytology, no ascites) has >90% 5-year disease-free survival with surgery and observation.
• High-risk early-stage ovarian carcinoma (grade 2-3, extra-ovarian spread, positive cytology, or ascites) has approximately 40% recurrence rate.
• Platinum-based adjuvant chemotherapy reduced recurrence rates by half compared to no adjuvant therapy in high-risk patients.

Conclusions:

• Risk stratification is crucial for managing early-stage ovarian carcinoma.
• Surgical resection followed by observation is adequate for low-risk disease.
• Adjuvant platinum-based chemotherapy is recommended for high-risk early-stage ovarian carcinoma to reduce recurrence.